ISLAMABAD: Gilead Sciences has said it is in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.
It also said it was negotiating long-term voluntary licenses with several generic drug makers in India and Pakistan to produce remdesivir for developing countries.
Gilead has patent exclusivity for the next 15 years on its potential Covid-19 treatment—but could be forced to license those patents to others.
Gilead Sciences Inc. has patent exclusivity on its potential Covid-19 treatment remdesivir for the next 15 years—poising the company for major profits if the drug is successful in treating.
Read more: Pakistan records 1,315 new cases single day highest spike in COVID-19 cases
